All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.

2024-11-08T12:23:08.000Z

Patient preferences and perspectives on topical treatments for plaque psoriasis

Nov 8, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in plaque psoriasis.


Results from an online survey of adults with plaque psoriasis in the United States were published by Amstrong et al. in the Journal of Dermatological Treatment, highlighting their preferences and perspectives on topical treatments. A total of 507 patients were included; mean age was 46.3 years and 47% were female. Most participants reported their psoriasis symptoms as mild (31%) or moderate (59%), and the average number of topical treatments received was 2.5.


Key learnings
Areas most affected by psoriasis were the scalp (56%), elbows (48%), legs (excluding knees; 41%), intertriginous areas (39%), arms (excluding elbows; 33%), and knees (32%). Psoriasis affecting the scalp, elbows, and legs had the greatest effect on quality of life. 
Topical therapies were the most preferred treatment option (76%), although 20% preferred pills and 4% injections. 
In total, 130 patients were somewhat or very dissatisfied with their topical therapy, for reasons such as ineffectiveness in clearing psoriasis (67%), the need for multiple daily applications (53%), and treatments being messy or greasy (38%). Dissatisfied patients reported more severe symptoms at diagnosis (18% vs 7%), preferred injection treatments (9% vs 2%), wanted once-daily dosing (63% vs 27%), and favored non-steroidal products (26% vs 16%) compared with satisfied patients. 
The most desired attributes to assist with topical treatment adherence were plaque improvement (68%), itch relief (68%), and ease of application (63%). 
90% of patients wanted more effective topical treatment options and a single topical therapy applicable to anywhere on the body. 
These findings highlight key aspects of experiences and preferences of patients with plaque psoriasis, which can guide future treatment strategies and inform patient-centered care. 

  1. Armstrong A, Young M, Seal MS, et al. Treatment burden and the perspectives of patients with psoriasis using topical treatments: Results from a national survey of adults with psoriasis in the United States. J Dermatolog Treat. 2024;35(1):2389174. DOI: 1080/09546634.2024.2389174

Your opinion matters

HCPs, what is your preferred format for educational content on the PsOPsA Hub?
9 votes - 65 days left ...

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox